| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Leukemia, Myeloid, Acute | 16 | 2025 | 167 | 10.130 |
Why?
|
| Myelodysplastic Syndromes | 7 | 2025 | 75 | 4.830 |
Why?
|
| Antibodies, Bispecific | 7 | 2025 | 29 | 4.340 |
Why?
|
| Immunotherapy, Adoptive | 6 | 2025 | 87 | 3.110 |
Why?
|
| Antineoplastic Agents | 6 | 2023 | 628 | 2.400 |
Why?
|
| Mutation | 7 | 2025 | 2456 | 2.300 |
Why?
|
| Hematologic Neoplasms | 3 | 2022 | 44 | 1.630 |
Why?
|
| Neoplasms, Second Primary | 2 | 2025 | 43 | 1.550 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 2021 | 65 | 1.410 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2024 | 328 | 1.340 |
Why?
|
| Humans | 59 | 2025 | 59389 | 1.150 |
Why?
|
| Tumor Suppressor Protein p53 | 3 | 2024 | 289 | 1.130 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2024 | 402 | 1.080 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2024 | 300 | 1.070 |
Why?
|
| Lymphoma, B-Cell | 2 | 2023 | 59 | 1.000 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 2 | 2024 | 25 | 0.930 |
Why?
|
| Clinical Trials as Topic | 2 | 2024 | 440 | 0.920 |
Why?
|
| Lymphoma, Follicular | 1 | 2024 | 16 | 0.900 |
Why?
|
| Dioxygenases | 1 | 2024 | 25 | 0.880 |
Why?
|
| Leukostasis | 1 | 2023 | 1 | 0.880 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2023 | 12 | 0.860 |
Why?
|
| Breast Neoplasms | 10 | 2021 | 1118 | 0.860 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2025 | 168 | 0.850 |
Why?
|
| Cell Cycle Proteins | 2 | 2025 | 384 | 0.820 |
Why?
|
| Lymphoma | 1 | 2023 | 99 | 0.810 |
Why?
|
| Neoplastic Stem Cells | 4 | 2024 | 196 | 0.800 |
Why?
|
| Hematology | 1 | 2022 | 11 | 0.780 |
Why?
|
| Neoplasms | 5 | 2025 | 1231 | 0.780 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2021 | 18 | 0.760 |
Why?
|
| Eosinophilia | 1 | 2021 | 30 | 0.750 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2021 | 50 | 0.740 |
Why?
|
| Stem Cell Transplantation | 2 | 2020 | 75 | 0.740 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2021 | 54 | 0.730 |
Why?
|
| Genes, Immunoglobulin Heavy Chain | 1 | 2020 | 2 | 0.720 |
Why?
|
| mRNA Cleavage and Polyadenylation Factors | 1 | 2021 | 61 | 0.720 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2021 | 68 | 0.710 |
Why?
|
| Gene Rearrangement | 1 | 2020 | 38 | 0.710 |
Why?
|
| Myocarditis | 1 | 2021 | 60 | 0.700 |
Why?
|
| Kidney Pelvis | 1 | 2020 | 10 | 0.700 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2022 | 139 | 0.690 |
Why?
|
| T-Lymphocytes | 1 | 2025 | 986 | 0.680 |
Why?
|
| Kidney | 1 | 2021 | 414 | 0.630 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2018 | 5 | 0.610 |
Why?
|
| Bone Marrow Cells | 4 | 2021 | 234 | 0.600 |
Why?
|
| Gap Junctions | 3 | 2012 | 16 | 0.600 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2018 | 21 | 0.600 |
Why?
|
| DNA Mismatch Repair | 1 | 2018 | 31 | 0.590 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2018 | 56 | 0.590 |
Why?
|
| DNA-Binding Proteins | 1 | 2024 | 1151 | 0.570 |
Why?
|
| Multiple Myeloma | 1 | 2022 | 325 | 0.570 |
Why?
|
| Brachytherapy | 1 | 2016 | 38 | 0.530 |
Why?
|
| Budd-Chiari Syndrome | 1 | 2015 | 5 | 0.500 |
Why?
|
| Vena Cava, Inferior | 1 | 2015 | 28 | 0.490 |
Why?
|
| Stromal Cells | 2 | 2012 | 65 | 0.490 |
Why?
|
| Stomach Neoplasms | 1 | 2015 | 69 | 0.480 |
Why?
|
| Tumor Microenvironment | 5 | 2023 | 140 | 0.470 |
Why?
|
| Prognosis | 4 | 2025 | 1597 | 0.450 |
Why?
|
| Lower Extremity | 1 | 2015 | 153 | 0.440 |
Why?
|
| Aged, 80 and over | 6 | 2025 | 5119 | 0.430 |
Why?
|
| Prostatic Neoplasms | 1 | 2016 | 339 | 0.430 |
Why?
|
| Cell Communication | 2 | 2012 | 124 | 0.410 |
Why?
|
| Aged | 7 | 2025 | 13406 | 0.410 |
Why?
|
| Disease Management | 2 | 2025 | 220 | 0.410 |
Why?
|
| Biomarkers, Tumor | 2 | 2015 | 461 | 0.410 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2020 | 1507 | 0.410 |
Why?
|
| Adenocarcinoma | 1 | 2015 | 323 | 0.410 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 3 | 2011 | 37 | 0.400 |
Why?
|
| Female | 20 | 2025 | 30724 | 0.390 |
Why?
|
| Disease Progression | 3 | 2024 | 1119 | 0.380 |
Why?
|
| Adult | 10 | 2025 | 15683 | 0.380 |
Why?
|
| Immune Tolerance | 2 | 2011 | 172 | 0.360 |
Why?
|
| Middle Aged | 8 | 2025 | 16314 | 0.360 |
Why?
|
| Bone Marrow | 2 | 2021 | 174 | 0.340 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2010 | 53 | 0.340 |
Why?
|
| Repressor Proteins | 3 | 2024 | 331 | 0.340 |
Why?
|
| T-Lymphocytes, Regulatory | 3 | 2012 | 207 | 0.330 |
Why?
|
| Cell Transdifferentiation | 2 | 2009 | 13 | 0.310 |
Why?
|
| Antibodies, Monoclonal | 2 | 2023 | 836 | 0.310 |
Why?
|
| Male | 8 | 2025 | 27747 | 0.300 |
Why?
|
| Transplantation Tolerance | 1 | 2008 | 65 | 0.290 |
Why?
|
| Regeneration | 1 | 2008 | 93 | 0.280 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 2 | 2024 | 19 | 0.270 |
Why?
|
| Sulfonamides | 2 | 2024 | 120 | 0.250 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2024 | 179 | 0.230 |
Why?
|
| Transplantation, Autologous | 1 | 2024 | 119 | 0.230 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2024 | 28 | 0.220 |
Why?
|
| Transplantation, Homologous | 1 | 2024 | 244 | 0.220 |
Why?
|
| Carboplatin | 2 | 2015 | 40 | 0.220 |
Why?
|
| Staurosporine | 1 | 2024 | 19 | 0.220 |
Why?
|
| Cell Line, Tumor | 6 | 2015 | 1368 | 0.220 |
Why?
|
| Coculture Techniques | 3 | 2012 | 95 | 0.220 |
Why?
|
| Tissue Donors | 1 | 2024 | 143 | 0.220 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 1 | 2024 | 82 | 0.220 |
Why?
|
| Phenylurea Compounds | 1 | 2023 | 30 | 0.220 |
Why?
|
| Benzothiazoles | 1 | 2023 | 19 | 0.220 |
Why?
|
| Molecular Targeted Therapy | 1 | 2024 | 121 | 0.210 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2025 | 263 | 0.210 |
Why?
|
| B-Cell Maturation Antigen | 1 | 2022 | 18 | 0.200 |
Why?
|
| Cell Cycle | 3 | 2015 | 382 | 0.200 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2024 | 170 | 0.200 |
Why?
|
| MicroRNAs | 4 | 2012 | 616 | 0.200 |
Why?
|
| Mice | 6 | 2021 | 10294 | 0.200 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2024 | 318 | 0.200 |
Why?
|
| Antigens, CD19 | 1 | 2021 | 19 | 0.190 |
Why?
|
| DNA Copy Number Variations | 1 | 2022 | 65 | 0.190 |
Why?
|
| Heart | 1 | 2024 | 274 | 0.190 |
Why?
|
| Young Adult | 5 | 2025 | 4272 | 0.190 |
Why?
|
| Stem Cell Niche | 1 | 2021 | 13 | 0.190 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2023 | 281 | 0.190 |
Why?
|
| Blast Crisis | 1 | 2021 | 10 | 0.190 |
Why?
|
| Maintenance Chemotherapy | 1 | 2021 | 14 | 0.190 |
Why?
|
| Genes, p53 | 1 | 2021 | 52 | 0.190 |
Why?
|
| Research Design | 1 | 2024 | 555 | 0.190 |
Why?
|
| Animals | 11 | 2021 | 19650 | 0.180 |
Why?
|
| Neoplasm, Residual | 1 | 2021 | 38 | 0.180 |
Why?
|
| Cell Dedifferentiation | 1 | 2021 | 4 | 0.180 |
Why?
|
| Remission Induction | 1 | 2021 | 137 | 0.180 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2020 | 193 | 0.180 |
Why?
|
| Nerve Tissue Proteins | 2 | 2015 | 418 | 0.180 |
Why?
|
| Treatment Outcome | 5 | 2020 | 5281 | 0.180 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2020 | 39 | 0.170 |
Why?
|
| Laser Therapy | 1 | 2020 | 36 | 0.170 |
Why?
|
| Hypercalcemia | 1 | 2020 | 8 | 0.170 |
Why?
|
| Splenic Neoplasms | 1 | 2020 | 8 | 0.170 |
Why?
|
| Abdomen | 1 | 2020 | 91 | 0.170 |
Why?
|
| Anthracyclines | 1 | 2020 | 10 | 0.170 |
Why?
|
| Cytarabine | 1 | 2020 | 32 | 0.170 |
Why?
|
| Allografts | 1 | 2020 | 44 | 0.170 |
Why?
|
| Clavicle | 1 | 2019 | 4 | 0.170 |
Why?
|
| Fracture Dislocation | 1 | 2019 | 3 | 0.170 |
Why?
|
| Cell Proliferation | 4 | 2021 | 941 | 0.170 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2021 | 276 | 0.170 |
Why?
|
| Arthroscopy | 1 | 2019 | 24 | 0.170 |
Why?
|
| Conservative Treatment | 1 | 2019 | 15 | 0.170 |
Why?
|
| United States Food and Drug Administration | 1 | 2020 | 85 | 0.160 |
Why?
|
| Fracture Fixation, Internal | 1 | 2019 | 49 | 0.160 |
Why?
|
| Genomics | 1 | 2022 | 319 | 0.160 |
Why?
|
| Phenotype | 2 | 2012 | 1137 | 0.150 |
Why?
|
| Cervical Vertebrae | 1 | 2019 | 101 | 0.150 |
Why?
|
| Triazines | 1 | 2018 | 16 | 0.150 |
Why?
|
| Aminopyridines | 1 | 2018 | 31 | 0.150 |
Why?
|
| Fractures, Bone | 1 | 2019 | 136 | 0.150 |
Why?
|
| Telemedicine | 1 | 2023 | 308 | 0.150 |
Why?
|
| Male Urogenital Diseases | 1 | 2016 | 5 | 0.140 |
Why?
|
| Neoplasm Grading | 1 | 2016 | 79 | 0.130 |
Why?
|
| Radiotherapy Dosage | 1 | 2016 | 81 | 0.130 |
Why?
|
| Prostate-Specific Antigen | 1 | 2016 | 66 | 0.130 |
Why?
|
| Radiation Injuries | 1 | 2016 | 62 | 0.130 |
Why?
|
| Gastrointestinal Diseases | 1 | 2016 | 69 | 0.130 |
Why?
|
| Chemokine CXCL12 | 2 | 2012 | 17 | 0.130 |
Why?
|
| Malaysia | 1 | 2015 | 2 | 0.130 |
Why?
|
| Trastuzumab | 1 | 2015 | 11 | 0.130 |
Why?
|
| Edema | 1 | 2015 | 42 | 0.120 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2015 | 20 | 0.120 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 396 | 0.120 |
Why?
|
| Syndrome | 1 | 2015 | 170 | 0.120 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2015 | 68 | 0.120 |
Why?
|
| Paclitaxel | 1 | 2015 | 90 | 0.120 |
Why?
|
| Neurons | 2 | 2012 | 863 | 0.120 |
Why?
|
| Fatigue | 1 | 2015 | 103 | 0.120 |
Why?
|
| Analgesics, Opioid | 1 | 2019 | 483 | 0.120 |
Why?
|
| Genes, Reporter | 2 | 2012 | 241 | 0.110 |
Why?
|
| Neoplasm Staging | 1 | 2015 | 448 | 0.110 |
Why?
|
| Cell Death | 1 | 2015 | 271 | 0.110 |
Why?
|
| Cell Culture Techniques | 1 | 2015 | 178 | 0.110 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 2013 | 9 | 0.110 |
Why?
|
| Skull Neoplasms | 1 | 2013 | 7 | 0.110 |
Why?
|
| Tissue Engineering | 1 | 2015 | 134 | 0.110 |
Why?
|
| Octamer Transcription Factor-3 | 1 | 2012 | 17 | 0.100 |
Why?
|
| Connexin 43 | 1 | 2012 | 13 | 0.100 |
Why?
|
| CD24 Antigen | 1 | 2012 | 18 | 0.100 |
Why?
|
| Hyaluronan Receptors | 1 | 2012 | 35 | 0.100 |
Why?
|
| Postoperative Complications | 1 | 2019 | 1204 | 0.100 |
Why?
|
| Neurokinin A | 1 | 2012 | 7 | 0.100 |
Why?
|
| Mental Disorders | 1 | 2020 | 720 | 0.100 |
Why?
|
| RNA, Messenger | 2 | 2015 | 1466 | 0.100 |
Why?
|
| Protein Kinase C | 1 | 2012 | 98 | 0.100 |
Why?
|
| RNA-Binding Proteins | 1 | 2015 | 386 | 0.100 |
Why?
|
| Pyroglyphidae | 1 | 2011 | 3 | 0.100 |
Why?
|
| Signal Transduction | 2 | 2012 | 2903 | 0.100 |
Why?
|
| Neurogenesis | 1 | 2012 | 60 | 0.090 |
Why?
|
| Allergens | 1 | 2011 | 50 | 0.090 |
Why?
|
| Tachykinins | 1 | 2011 | 9 | 0.090 |
Why?
|
| Adult Stem Cells | 2 | 2010 | 28 | 0.090 |
Why?
|
| Immunotherapy | 1 | 2013 | 228 | 0.090 |
Why?
|
| Cell Division | 1 | 2012 | 443 | 0.090 |
Why?
|
| Follow-Up Studies | 1 | 2016 | 2338 | 0.090 |
Why?
|
| Spinal Cord Injuries | 1 | 2011 | 38 | 0.090 |
Why?
|
| Regenerative Medicine | 1 | 2010 | 19 | 0.090 |
Why?
|
| Transfection | 1 | 2012 | 675 | 0.090 |
Why?
|
| Immune System | 1 | 2012 | 129 | 0.090 |
Why?
|
| Lymphopenia | 1 | 2010 | 35 | 0.090 |
Why?
|
| K562 Cells | 1 | 2010 | 57 | 0.080 |
Why?
|
| Neoplasm Invasiveness | 1 | 2011 | 248 | 0.080 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2012 | 474 | 0.080 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2010 | 147 | 0.080 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2010 | 170 | 0.080 |
Why?
|
| Guided Tissue Regeneration | 1 | 2009 | 4 | 0.080 |
Why?
|
| Killer Cells, Natural | 1 | 2010 | 218 | 0.080 |
Why?
|
| Cell Growth Processes | 1 | 2008 | 36 | 0.070 |
Why?
|
| Adolescent | 4 | 2021 | 5838 | 0.070 |
Why?
|
| Cells, Cultured | 4 | 2012 | 2092 | 0.070 |
Why?
|
| Immunization | 1 | 2008 | 128 | 0.070 |
Why?
|
| Pluripotent Stem Cells | 1 | 2008 | 68 | 0.070 |
Why?
|
| Asthma | 1 | 2011 | 460 | 0.070 |
Why?
|
| United States | 1 | 2020 | 7426 | 0.070 |
Why?
|
| Neurodegenerative Diseases | 1 | 2009 | 134 | 0.070 |
Why?
|
| Transduction, Genetic | 1 | 2008 | 228 | 0.060 |
Why?
|
| Cell Differentiation | 2 | 2009 | 1304 | 0.060 |
Why?
|
| Cytokines | 1 | 2009 | 915 | 0.060 |
Why?
|
| Retrospective Studies | 3 | 2021 | 6071 | 0.060 |
Why?
|
| Gene Expression Regulation | 1 | 2011 | 1552 | 0.060 |
Why?
|
| Methyltransferases | 1 | 2024 | 52 | 0.050 |
Why?
|
| Safety-net Providers | 1 | 2023 | 29 | 0.050 |
Why?
|
| Mice, Inbred BALB C | 2 | 2015 | 868 | 0.050 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2024 | 327 | 0.050 |
Why?
|
| Healthy Volunteers | 1 | 2021 | 66 | 0.040 |
Why?
|
| Epigenesis, Genetic | 1 | 2024 | 357 | 0.040 |
Why?
|
| Histones | 1 | 2024 | 457 | 0.040 |
Why?
|
| Blotting, Western | 2 | 2012 | 583 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2012 | 527 | 0.040 |
Why?
|
| Azacitidine | 1 | 2020 | 13 | 0.040 |
Why?
|
| Wnt Signaling Pathway | 1 | 2021 | 71 | 0.040 |
Why?
|
| Exosomes | 1 | 2021 | 44 | 0.040 |
Why?
|
| Splenectomy | 1 | 2020 | 41 | 0.040 |
Why?
|
| Shoulder | 1 | 2019 | 24 | 0.040 |
Why?
|
| Fracture Healing | 1 | 2019 | 24 | 0.040 |
Why?
|
| Diskectomy | 1 | 2019 | 29 | 0.040 |
Why?
|
| Biopsy | 1 | 2021 | 410 | 0.040 |
Why?
|
| DNA | 1 | 2024 | 805 | 0.040 |
Why?
|
| DNA Repair | 1 | 2021 | 242 | 0.040 |
Why?
|
| Risk | 1 | 2019 | 364 | 0.040 |
Why?
|
| Pandemics | 1 | 2023 | 617 | 0.040 |
Why?
|
| Spinal Fusion | 1 | 2019 | 124 | 0.040 |
Why?
|
| Recovery of Function | 1 | 2019 | 270 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2020 | 931 | 0.030 |
Why?
|
| Pregnancy | 1 | 2023 | 2213 | 0.030 |
Why?
|
| Laparoscopy | 1 | 2020 | 427 | 0.030 |
Why?
|
| Cell Count | 1 | 2015 | 127 | 0.030 |
Why?
|
| Tissue Scaffolds | 1 | 2015 | 79 | 0.030 |
Why?
|
| Proteomics | 1 | 2015 | 263 | 0.030 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2013 | 35 | 0.030 |
Why?
|
| Tumor Escape | 1 | 2013 | 16 | 0.030 |
Why?
|
| Adoptive Transfer | 1 | 2013 | 147 | 0.030 |
Why?
|
| Cell Survival | 1 | 2015 | 559 | 0.030 |
Why?
|
| Antibodies | 1 | 2013 | 179 | 0.030 |
Why?
|
| History, 21st Century | 1 | 2013 | 162 | 0.030 |
Why?
|
| Forecasting | 1 | 2013 | 221 | 0.030 |
Why?
|
| History, 20th Century | 1 | 2013 | 224 | 0.020 |
Why?
|
| Excitatory Postsynaptic Potentials | 1 | 2012 | 44 | 0.020 |
Why?
|
| Cats | 1 | 2012 | 81 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2012 | 191 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2012 | 258 | 0.020 |
Why?
|
| Cellular Microenvironment | 1 | 2011 | 20 | 0.020 |
Why?
|
| Species Specificity | 1 | 2012 | 329 | 0.020 |
Why?
|
| Adipogenesis | 1 | 2012 | 71 | 0.020 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2011 | 15 | 0.020 |
Why?
|
| Activating Transcription Factors | 1 | 2011 | 11 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-jun | 1 | 2011 | 26 | 0.020 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2012 | 62 | 0.020 |
Why?
|
| Antigens, Surface | 1 | 2012 | 192 | 0.020 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2011 | 46 | 0.020 |
Why?
|
| Transcription Factor AP-1 | 1 | 2011 | 41 | 0.020 |
Why?
|
| Response Elements | 1 | 2011 | 43 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2013 | 847 | 0.020 |
Why?
|
| Co-Repressor Proteins | 1 | 2011 | 22 | 0.020 |
Why?
|
| Hypersensitivity | 1 | 2011 | 63 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 2013 | 365 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2012 | 365 | 0.020 |
Why?
|
| Tretinoin | 1 | 2011 | 49 | 0.020 |
Why?
|
| Osteogenesis | 1 | 2012 | 140 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2011 | 223 | 0.020 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2011 | 238 | 0.020 |
Why?
|
| Inflammation Mediators | 1 | 2011 | 171 | 0.020 |
Why?
|
| Wound Healing | 1 | 2011 | 174 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2012 | 883 | 0.020 |
Why?
|
| Child | 1 | 2019 | 4189 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 2012 | 391 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 2011 | 743 | 0.020 |
Why?
|
| Poly-ADP-Ribose Binding Proteins | 1 | 2009 | 9 | 0.020 |
Why?
|
| Binding Sites | 1 | 2011 | 881 | 0.020 |
Why?
|
| Dendritic Cells | 1 | 2011 | 515 | 0.020 |
Why?
|
| Zebrafish | 1 | 2011 | 326 | 0.020 |
Why?
|
| Interdisciplinary Communication | 1 | 2009 | 103 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2012 | 1997 | 0.020 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2009 | 210 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2009 | 278 | 0.020 |
Why?
|
| Protein Binding | 1 | 2011 | 1555 | 0.020 |
Why?
|
| Genetic Therapy | 1 | 2013 | 733 | 0.020 |
Why?
|
| NF-kappa B | 1 | 2009 | 460 | 0.020 |
Why?
|
| Models, Biological | 1 | 2011 | 1143 | 0.020 |
Why?
|
| Inflammation | 1 | 2009 | 1099 | 0.010 |
Why?
|